WHO ICTRP trial
Effect of Spironolactone in Acute kidney disease
CTRI/2020/01/023081 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2020/01/023081 |
|---|---|
| Public title | Effect of Spironolactone in Acute kidney disease |
| Scientific title | Effect of spironolactone on renal outcome in acute kidney disease: an open label randomised controlled trial |
| Primary sponsor | Government of West Bengal |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | India |
| Conditions | Health Condition 1: N178- Other acute kidney failure |
| Interventions | Intervention1: Spironolactone: Spironolactone will be started at a dose of 25 mg once daily and increased to 50 mg once daily at 4 weeks,provided the serum potassium is no more than 4.5 mmol/l.The dose of the drug will be reduced if the… |
| Registration date | Jan 31, 2020 |
| Target size | 34 |
| Secondary IDs | Nil |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: